Clinical trials: Drug Eluting Stents
Coronary Heart Disease
TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)
The goal of the TAXUS™ Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study is to evaluate real world clinical outcomes data for the TAXUS™ Element™ Coronary Stent System in unselected…
- Trial name
- TE-Prove (NCT01242696)
- Testing
- Coronary artery stenting
- Where
- 37 sites in Belgium, France and 8 more
- Volunteers
- 1,014 people
- Sponsor
- Boston Scientific Corporation
Stable Coronary Disease, Unstable Coronary Disease
Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen
To evaluate the safety and efficacy of the Janus OPTIMA Tacrolimus-Eluting Stent (Optima TES, CID) for the treatment of de novo coronary lesions when associated with short-term (two months) dual antiplatelet (aspirin +…
- Conditions
- Stable Coronary Disease, Unstable Coronary Disease, Documented Silent Ischemia
- Trial name
- BEST (NCT01122719)
- Testing
- Drug Eluting Stent
- Where
- 2 sites in Brazil, Italy
- Volunteers
- 16 people
- Sponsor
- CID - Carbostent & Implantable Devices
Coronary Artery Disease
DEBlue Stent vs Cypher Stent in the Treatment of Advanced Coronary Artery Disease
The aim of the study is to assess the safety and efficacy of the Paclitaxel-eluting SeQuent Please S stent system (DEBlue) in the treatment of stenoses in native coronary arteries with nominal stent diameters between ≥ 2.5 mm and…
- Trial name
- PEPCADIII (NCT00473772)
- Testing
- DEBlue stent vs. Cypher stent
- Where
- 16 sites in Belgium, Czechia and 6 more
- Volunteers
- 643 people
- Sponsor
- University Hospital, Saarland
Coronary Artery Disease, Drug-coated Balloon
Long-term Efficacy of Drug-coated Balloon Versus Drug-eluting Stent in Large de Novo Coronary Lesions
To evaluate the efficacy of drug-coated balloon versus drug-eluting stent for the treatment of large de novo coronary lesions(RVD=2.75~4.0mm).
- Trial name
- NCT05101005
- Testing
- Drug-Coated Balloon, Sirolimus-Eluting Stent
- Volunteers
- 400 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Acute Coronary Syndrome
DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial
To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of…
- Trial name
- ONE-PASS (NCT05305482)
- Testing
- Drug-coated stent, Drug-eluting stent
- Where
- South Korea
- Volunteers
- 3,520 people
- Sponsor
- Yonsei University
Femoropopliteal In-Stent Restenosis (ISR)
Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis
Femoropopliteal in-stent restenosis (ISR) remains an important cause of recurrent symptoms and repeat revascularization after lower-extremity endovascular treatment.
- Trial name
- NCT07277218
- Testing
- Drug-Coated Balloon-First Strategy, Eluvia Drug-Eluting Stent-First Strategy
- Where
- 10 sites in China
- Volunteers
- 600 people
- Sponsor
- Chunshui He
Coronary Disease
Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I
Single center randomized parallel group study to determine if: 1. there is a temporary increase in platelet reactivity after abrupt discontinuation of clopidogrel due to a potential rebound phenomenon. 2.
- Trial name
- PRACTICE I (NCT00684359)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medstar Health Research Institute
Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery
Predictors and Long-term Incidence of In-stent Restenosis After Chronic Total Occlusion Percutaneous Coronary Intervention
The goal of this clinical trial is to describe the long-term (≥ 3 years) patency of coronary artery stents following chronic total occlusion percutaneous coronary intervention (CTO PCI).
- Conditions
- Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery, Chronic Total Occlusion (CTO)
- Trial name
- NCT07473596
- Testing
- chronic total occlusion percutaneous coronary intervention (CTO PCI), coronary computed tomography angiography, invasive coronary angiography
- Where
- Finland
- Volunteers
- 294 people
- Sponsor
- Lauri Mansikkaniemi
Percutaneous Coronary Intervention (PCI), Coronary Artery Disease (CAD)
Drug Eluting Balloon Angioplasty Versus Everolimus Platinum Chrome Stent
Randomized, open-label, single-center, non-inferiority clinical trial to compare late lumen loss (LLL) at 12 months in Tunisian population undergoing coronary percutaneous intervention between Drug Eluting Balloon treated group…
- Conditions
- Percutaneous Coronary Intervention (PCI), Coronary Artery Disease (CAD), De Novo Stenosis
- Trial name
- DEBATE (NCT05516446)
- Testing
- DEB for de Novo Lesions, DES for de Novo Lesions
- Where
- Tunisia
- Volunteers
- 290 people
- Sponsor
- General Administration of Military Health, Tunisia
Coronary Artery Disease
Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)
This is randomized-controlled trial to evaluate the difference of composite of cardiac death, myocardial infarction, or Stroke between the dual antiplatelet therapy group and the aspirin monotherapy group after 1-year of…
- Trial name
- DES-LATE (NCT01186146)
- Testing
- Aspirin monotherapy, Aspirin,Clopidogrel
- Where
- 19 sites in South Korea
- Volunteers
- 5,000 people
- Sponsor
- Seung-Jung Park
Coronary Disease, Drug Eluting Stent
Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent
Length of DAT (Dual Antiplatelet therapy) represents one of the most challenging choices for interventional cardiologist. Prolonged DAT reduces risk of subsequent MI (Myocardial Infarction) with an increase in major bleedings…
- Conditions
- Coronary Disease, Drug Eluting Stent, STEMI
- Trial name
- CHANCE (NCT03622203)
- Testing
- Biofreedom
- Volunteers
- 1,000 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Coronary Artery Disease, Percutaneous Coronary Intervention
Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration
this study is an individual patient level meta-analysis of randomized clinical trials, to evaluate the influence of ethnicity, to study whether the relative tradeoff between ischemia and bleeding is distinct by ethnicity.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03338335
- Testing
- prolonged DAPT
- Where
- South Korea
- Volunteers
- 16,000 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease, Drug-eluting Stent
Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention
Clinical trial with an "European Community marked" medical device in patients with ischemic heart disease and clinical indication of coronary revascularization with drug-eluting stent.
- Trial name
- NCT03049657
- Testing
- Angiolite, Xience
- Where
- 11 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Cardiva2 S.L.
Coronary Artery Disease
Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE
Prospective, multicenter, single arm registry to monitor post-market clinical outcomes of patients treated with Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer.
- Trial name
- LATITUDE (NCT03471234)
- Testing
- Angioplasty
- Where
- 2 sites in Brazil
- Volunteers
- 299 people
- Sponsor
- Scitech Produtos Medicos SA
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Observational Prospective Study OPTIMA II - Follow-up
The current follow-up study was planned to reveal the rates of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) during 4-year follow-up in patients participated in OPTIMA study.
- Trial name
- OPTIMAII (NCT02099565)
- Where
- Russia
- Volunteers
- 572 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)
Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)
It is a multi-center randomized clinical trial (RCT) which will enroll 3746 patients with acute coronary syndrome (ACS) concomitant non-valvular atrial fibrillation (NVAF) and undergoing new generation drug eluting stent (DES)…
- Trial name
- NCT03234114
- Testing
- Triple antithrombotic therapy, Dual antithrombotc therapy-1, Dual antithrombotc therapy-2
- Where
- China
- Volunteers
- 3,746 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease
Orsiro™ Drug Eluting Stent in Routine Clinical Practice
The purpose of this study is to evaluate effectiveness and safety of Orsiro™ Drug Eluting Stent in Routine Clinical Practice
- Trial name
- IRIS ORSIRO (NCT02039739)
- Testing
- Orsiro™ Drug Eluting Stent group
- Where
- 18 sites in South Korea
- Volunteers
- 1,007 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
BiOSS Study (BiOSS LIM C Stent Registry in Bifurcated Lesions)
The BIOSS Lim C pharmacoactive Stent has characteristics of design that makes it very suitable for the treatment of bifurcational lesions .
- Trial name
- BIOSS (NCT03475563)
- Testing
- Coronary angioplasty with stent implantation
- Where
- 3 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Coronary Artery Disease
A Study Comparing Two Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study
Stent coverage and neo-intimal growth can be evaluated in-detail by intracoronary optical coherence tomography (OCT), which is a catheter-based imaging technique. It is performed as part of the PCI procedure.
- Trial name
- OCT-ORION (NCT01742507)
- Testing
- Resolute Integrity Stent, Biomatrix stent
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
Critical Limb Ischemia
The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs.
- Trial name
- SAVAL (NCT03551496)
- Testing
- Drug Eluting Stent - Below the Knee, Standard PTA Control Arm
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation